Cardiac Effects of Endothelin-1 (ET-1) and Related C-Terminal Peptide Fragment: Increased Inotropy or Contribution to Heart Failure?

Physiological Research

Volumn 52, Issue 6, 2003, Pages 701-708

  Drimal J ^a   Knezl, V ^a   Drimal Jr J ^b   Drimal D ^c   Bauerova K ^a   Kettmann, V ^a   Doherty, A M ^d   Stefek M ^a  

^a INSTITUTE OF EXPERIMENTAL PHARMACOLOGY AND TOXICOLOGY   (Slovakia)

^b Slovak Gas Industry ^*  (Slovakia)

^c SLOVAK UNIVERSITY OF TECHNOLOGY   (Slovakia)

^d PFIZER INC   (United States)

Author keywords

BQ788; Endothelin antagonists; Endothelin 1; ETA and ETB receptors; IRL1620; PD142893; PD151242; PD155080

Indexed keywords

3 BENZYL 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 2 BUTENOIC ACID; ENDOTHELIN 1; ENDOTHELIN 1 [1-21]; ENDOTHELIN 1 [8-21]; ENDOTHELIN 1 CARBOXY TERMINAL PEPTIDE FRAGMENT; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR AGONIST; ENDOTHELIN RECEPTOR AGONIST; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; N ACETYL 10,11 DIHYDRO 5H DIBENZO[A,D]CYCLOHEPTEN 5 YLGLYCYLLEUCYLASPARTYLISOLEUCYLISOLEUCYLTRYPTOPHAN; PEPTIDE FRAGMENT; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CHRONOTROPISM; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOWN REGULATION; HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; INOTROPISM; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT;

AMINO ACID SEQUENCE; ANIMALS; CORONARY CIRCULATION; DIOXOLES; ENDOTHELIN-1; ENDOTHELINS; HEART; HEART FAILURE, CONGESTIVE; HEART RATE; HUMANS; MALE; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; PERFUSION; PIPERIDINES; RATS; RATS, WISTAR; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE;

EID: 0345869783     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. 2α stimulates hypertrophic growth of cultured neonatal rat ventricular myocytes. J Biol Chem 271: 1179-1186, 1996.
2. BEYER ME, SLESAK G, HOFFMEISTER HM: Significance of endothelin B receptors for myocardial contractility and myocardial energy metabolism. J Pharmacol Exp Ther 278: 1228-1234, 1996.
3. B receptors in local clearance of endothelin-1 in rat heart. Studies with antagonists PD155080 and BQ788. FEBS Lett 396: 238-242, 1996.
4. DENG SJ, MACKENZIE CR, SADOWSKA J, YOUNG NM, BUNDLE DR, NARANG SA: Selection of antibody single-chain variable fragments with improved carbohydrate binding by phase display. J Biol Chem 269: 9533-9538, 1994.
5. DOHRING HJ, DEHNERT H: The isolated perfused warm-blooded heart according to Langendorff. In: Methods in Experimental Physiology and Pharmacology, Biomesstechnik-Verlag March GmbH, March, Germany, 1988, p 101.
6. B receptor down-regulation. Physiol Res 48: 9-19, 1999.
7. B receptor down-regulation in human tumor cells. Eur J Pharmacol 396: 19-22, 2000.
8. DŘÍMAL J, DŘÍMAL J,Jr, ORLICKÝ J, BAUEROVÁ K, JANEČEK A, KETTMANN V, DŘÍMAL D: Effects of human peptide endothelin-1 and two of its sterically unrestrained C-terminal fragments in coronary vascular smooth muscle. J Gen Physiol Biophys 21: 5-16, 2002.
9. ENDOH M, NOROTA I, YANG HT, FUJITA S, TAKANASHI M: The positive inotropic effect of phosphoinositide induced by endothelin-3 in rabbit ventricular myocardium: Inhibition by a selective antagonist of ETA receptors FR139317. J Pharmacol Exp Ther 277: 61-70, 1996.
10. GU XH, OU RC, CASLEY DJ, DALLY MJ, NAYLER WG: Effects of age on endothelin-1 binding sites in rat ventricular membranes. J Cardiovasc Pharmacol 19: 764-769, 1992.
11. GRANTHAM JA, SCHIRGER JA, WENNBERG PW, SANDBERG S, HEUBLEIN DM, SUBKOWSKI T, BURNETT JC: Modulation of functionally active endothelin-converting enzyme by chronic neutral endopeptidase inhibition in experimental atherosclerosis Circulation 101: 1976-1989, 2000.
12. HILAL-DANDAN R, VILLEGAS S, GONZALEZ A, BRUNTON LL: The quasi-irreversible nature of endothelin binding and G protein-linked signaling in cardiac myocytes. J Pharmacol Exp Ther 281: 267-273, 1997.
13. KATOH H, TERADA H, IIMURO M, SUGIYAMA S, QING K, SATOH H, HAYASHI H: Heterogeneity and underlying mechanism for inotropic action of endothelin-1 in rat ventricular myocytes. Br J Pharmacol 123: 1343-1350, 1998.
14. B receptors, and ECE and distribution of endothelin-1 in failing rat heart. Am J Physiol. 276: H1197-H1206, 1999.
15. MASAKI T, YANAGISAWA M, GOTO K: Physiology and pharmacology of endothelins. Med Res Rev 12: 391-421, 1992.
16. McCARTHY PA, GROCOTT-MASON R, PENDERGAST BD, SHAH AM: Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart. Circulation 101: 142-148, 2000.
17. MISHIMA T, TANIMURA M, SUZUKI G, TODOR A, SHAROV VG, GOLDSTEIN S, SABBAH HN: Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure. J Am Coll Cardiol 35: 222-229, 2000.
18. MODESTI PA, VANNI S, PANICCIA R, BANDINELLI B, BERTOLOZZI I, POLIDORI G, SANI G, NERI SERNERI GG: Characterization of endothelin-1 receptor subtypes in isolated human cardiomyocytes. J Cardiovasc Pharmacol 34: 333-339, 1999.
19. MOLENAAR P, O'REILLY G, SHARKEY A, KUC RE, HARDING DP, PLUMPTON C, GRESHAW GA, DAVENPORT AP: Characterization and localization of endothelin receptor subtypes in human atrioventricular conducting system and myocardium. Circ Res 72: 526-588, 1993.
20. 125I]-PD151242 for human rat and porcine endothelin ETA receptors in the heart. Br J Pharmacol 114: 297-302, 1995.
21. SAKAI S, MIYAGUCHI T, SAKURAI T, KASUYA Y, IHARA M, YAMAGUCHI I, GOTO K, SUGISHITA Y: Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Circulation 93: 1214-1222, 1996.
22. SOKOLOVSKY M, CALDRON R, KLOOG Z, BDOLAH A, EINDIG F, BLUMBERG S, FLEMINGER G: Endothelins are more sensitive than sarafotoxins to neutral endopeptidase: possible physiological significance. Proc Natl Acad Sci USA 87: 4702-4706, 1990.
23. STEWART DJ, KUBAC G, COSTELLO KB, CERNACEK P: Increased plasma endothelin-1 in the early hours of acute myocardial infarction. J Am Coll Cardiol 18: 38-43, 1991.
24. B receptor. Biochem Biophys Res Commun 184: 953-959, 1992.
25. TAKEISHI Y, PING P, BOLLI R, KIRKPATRICK DL, HOIT BD, WALSH RA: Transgenic overexpression of constitutively active PKCε causes concentric cardiac hypertrophy. Circ Res 86: 1218-1213, 2000.
26. TOMODA H: Plasma endothelin-1 in acute myocardial infarction with heart failure. Am Heart J 123: 667-672, 1993.
27. WALLACE BA, JANES RW: The crystal structure of human endothelin-1 and how it relates to receptor binding. J Cardiovasc Pharmacol 26 (Suppl 3): S250-253, 1995.
28. WALLACE BA, JANES RW, BASSOLINO DA, KRISTEK SA: A comparison of X-ray and NMR structures for human endothelin-1. Protein Sci 4: 75-83, 1995.
29. ZHU Y, YANG HT, ENDOH M: Negative chronotropic and inotropic effects of endothelin isopeptides in mammalian cardiac muscle. Am J Physiol 273: H119-H127, 1997.
30. ZHU W, ZOU Y, SHIOJIMA I, KUDOH S, AIKAWA R, HAYASHI D, MIZUKAMI M, TOKO H, SHIBASAKI F, YAZAKI Y, NAGAI R, KOMURO I: Calcium/calmodulin-dependent kinase II and calcineurin play critical roles in ET-1 induced cardiomyocyte hypertrophy. J Biol Chem 275: 15239-15245, 2000.
31. ZOLK O, QUATTEK J, SITZLER G, SCHRADER T, NICKENING G, SCHNABEL P, SHIMADA K, TAKAHASHI M, BOHM M: Expression of endothelin-1 endothelin-converting enzyme and endothelin receptors in chronic heart failure. Circulation 9: 2118-2123, 1999.